Table 4.
Estimated mean difference between positive and negative participants in 1-, 3-, and 5-year change from baseline on composite Z score for each intervention group compared to the control group
| Groups | Estimated difference between positive and negative subjects for each intervention group (95% CI) | P value | ||
|---|---|---|---|---|
| Unadjusted | Adjusteda | Unadjusted | Adjusteda | |
| 1-year ITT MAPT analysis (n = 483) | ||||
| Multidomain plus omega 3 | 0.1677 (-0.0498; 0.3852) | 0.1693 (-0.0490; 0.3875) | 0.1305 | 0.1282 |
| Omega 3 alone | 0.0255 (-0.1916; 0.2427) | -0.0060 (-0.2277; 0.2156) | 0.8176 | 0.9573 |
| Multidomain plus placebo | 0.1237 (-0.0931; 0.3404) | 0.1055 (-0.1145; 0.3255) | 0.2629 | 0.3467 |
| 1-year per-protocol MAPT analysis (n = 457) | ||||
| Multidomain plus omega 3 | 0.2147 (-0.0110; 0.4404) | 0.2194 (-0.0061; 0.4450) | 0.0623 | 0.0565 |
| Omega 3 alone | 0.0380 (-0.1830; 0.2590) | 0.0079 (-0.2170; 0.2327) | 0.7356 | 0.9453 |
| Multidomain plus placebo | 0.1207 (-0.1033; 0.3446) | 0.0954 (-0.1311; 0.3219) | 0.2904 | 0.4084 |
| 3-year ITT MAPT analysis (n = 483) | ||||
| Multidomain plus omega 3 | 0.2893 (-0.0301; 0.6087) | 0.3067 (-0.0110; 0.6244) | 0.0757 | 0.0584 |
| Omega 3 alone | 0.0941 (-0.2253; 0.4135) | 0.1063 (-0.2169; 0.4295) | 0.5628 | 0.5181 |
| Multidomain plus placebo | 0.1602 (-0.1567; 0.4771) | 0.1218 (-0.1969; 0.4406) | 0.3209 | 0.4528 |
| 3-year per-protocol MAPT analysis (n = 457) | ||||
| Multidomain plus omega 3 | 0.3442 (0.0137; 0.6747) | 0.3695 (0.0424; 0.6967) | 0.0413 | 0.0269 |
| Omega 3 alone | 0.1038 (-0.2201; 0.4277) | 0.1186 (-0.2078; 0.4450) | 0.5291 | 0.4754 |
| Multidomain plus placebo | 0.1452 (-0.1810; 0.4714) | 0.1008 (-0.2261; 0.4277) | 0.3819 | 0.5447 |
| 5-year ITT MAPT-PLUS analysis (n = 483) | ||||
| Multidomain plus omega 3 | 0.2932 (-0.1331; 0.7196) | 0.2738 (-0.1520; 0.6997) | 0.1768 | 0.2065 |
| Omega 3 alone | -0.0645 (-0.4785; 0.3495) | -0.1297 (-0.5534; 0.2940) | 0.7592 | 0.5471 |
| Multidomain plus placebo | 0.0261 (-0.4040; 0.4563) | -0.0475 (-0.4828; 0.3878) | 0.9049 | 0.8300 |
| 5-year per-protocol MAPT-PLUS analysis (n = 457) | ||||
| Multidomain plus omega 3 | 0.3611 (-0.0784; 0.8006) | 0.3479 (-0.0903; 0.7861) | 0.1069 | 0.1191 |
| Omega 3 alone | -0.0635 (-0.4862; 0.3591) | -0.1248 (-0.5571; 0.3075) | 0.7674 | 0.5701 |
| Multidomain plus placebo | 0.0045 (-0.4389; 0.4478) | -0.0790 (-0.5277; 0.3697) | 0.9841 | 0.7292 |
ITT Intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score